neutralization tests

Summary

Summary: Titration of an antiserum by testing a series of dilutions of virus or immune serum to a given end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).

Top Publications

  1. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  2. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  3. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
  4. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
  5. pmc Antibody recognition of a highly conserved influenza virus epitope
    Damian C Ekiert
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 324:246-51. 2009
  6. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  7. pmc Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses
    Jianhua Sui
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street JFB 826, Boston, Massachusetts 02115, USA
    Nat Struct Mol Biol 16:265-73. 2009
  8. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
  9. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
  10. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996

Detail Information

Publications337 found, 100 shown here

  1. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  2. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  3. pmc Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  4. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
    ..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
  5. pmc Antibody recognition of a highly conserved influenza virus epitope
    Damian C Ekiert
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 324:246-51. 2009
    ..The CR6261 epitope identified here should accelerate the design and implementation of improved vaccines that can elicit CR6261-like antibodies, as well as antibody-based therapies for the treatment of influenza...
  6. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  7. pmc Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses
    Jianhua Sui
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street JFB 826, Boston, Massachusetts 02115, USA
    Nat Struct Mol Biol 16:265-73. 2009
    ..Our data further suggest that this region is recalcitrant to neutralization escape and that nAb-based immunotherapy is a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses...
  8. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  9. pmc Structural definition of a conserved neutralization epitope on HIV-1 gp120
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 445:732-7. 2007
    ..A site of vulnerability, related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize HIV-1...
  10. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  11. pmc Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    Ann J Hessell
    Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA
    PLoS Pathog 5:e1000433. 2009
    ..The results raise the possibility that some epitopes on HIV may be better vaccine targets than others and support targeting the glycan shield of the envelope...
  12. pmc Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
    Birke Bartosch
    Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Superieure de Lyon, 69364 Lyon Cedex 07, France
    J Exp Med 197:633-42. 2003
    ..Altogether, these studies indicate that these pseudo-particles may mimic the early infection steps of parental HCV and will be suitable for the development of much needed new antiviral therapies...
  13. ncbi Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 458:636-40. 2009
    ..Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120...
  14. ncbi Complete replication of hepatitis C virus in cell culture
    Brett D Lindenbach
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:623-6. 2005
    ..HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals...
  15. pmc The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity
    Martina Beltramello
    Institute for Research in Biomedicine, Bellinzona 6500, Switzerland
    Cell Host Microbe 8:271-83. 2010
    ..Our findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue...
  16. pmc Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    J R Mascola
    Division of Retrovirology, Walter Reed Army Institute of Research and Henry M Jackson Foundation, Rockville, Maryland 20850, USA
    J Virol 73:4009-18. 1999
    ..These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease...
  17. pmc Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells
    Mark Throsby
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 3:e3942. 2008
    ..Furthermore, there are 16 different HA subtypes and no certainty the next pandemic will be caused by an H5 subtype, thus it is important to develop prophylactic and therapeutic interventions that provide heterosubtypic protection...
  18. ncbi Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
    Ann J Hessell
    Department of Immunology and Microbial Science and International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    Nat Med 15:951-4. 2009
    ..Overall, the results imply that lower amounts of antibody than previously considered protective may provide benefit in the context of typical human exposure to HIV-1...
  19. pmc Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, Washington 98109, USA
    J Virol 83:757-69. 2009
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action...
  20. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  21. ncbi Neutralization and antibody-dependent enhancement of dengue viruses
    Scott B Halstead
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Adv Virus Res 60:421-67. 2003
  22. pmc Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
    Melissa D Simek
    International AIDS Vaccine Initiative, New York, NY 10028, USA
    J Virol 83:7337-48. 2009
    ..These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design...
  23. ncbi Identification and characterization of a cross-neutralization epitope of Enterovirus 71
    Chia Chyi Liu
    Vaccine R and D Center, National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan
    Vaccine 29:4362-72. 2011
    ..Thus, VP2-28 could be used as the surrogate biomarker in the potency testing of candidate EV71 vaccines...
  24. pmc The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
    Rogier W Sanders
    Dept of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Virol 76:7293-305. 2002
    ....
  25. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  26. pmc Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
    P Roben
    Department of Immunology, Scripps Research Institute, La Jolla, California 92037
    J Virol 68:4821-8. 1994
    ..Apparently, subtle differences in the gp120 epitope recognized allow some members of the group of anti-CD4bs antibodies to bind to the functionally relevant envelope glycoprotein complex and to neutralize virus more efficiently...
  27. pmc Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus
    Theodore Oliphant
    Department of Molecular Microbiology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St Louis, Missouri 63110, USA
    Nat Med 11:522-30. 2005
    ..In postexposure therapeutic trials in mice, a single dose of humanized E16 protected mice against WNV-induced mortality, and may therefore be a viable treatment option against WNV infection in humans...
  28. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  29. pmc A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection
    Stéphanie Longet
    Department of Urology, CHUV, c o IMUL, Bugnon 48, 1011 Lausanne, Switzerland
    J Virol 85:13253-9. 2011
    ..The results clearly demonstrate that, remarkably, the in vivo assay is substantially more sensitive than in vitro PsV neutralization and thus may be better suited for studies to establish correlates of protection...
  30. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  31. pmc Efficient intracellular assembly of papillomaviral vectors
    Christopher B Buck
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
    J Virol 78:751-7. 2004
    ..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
  32. pmc The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120
    Christopher N Scanlan
    The Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom
    J Virol 76:7306-21. 2002
    ....
  33. pmc Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
    P W Parren
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:8340-7. 2001
    ..The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study...
  34. pmc Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
    E S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 81:6187-96. 2007
    ..These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection...
  35. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  36. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
    ..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
  37. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
    ..Our data indicated that inactivated virus is the choice of vaccine preparation capable of fulfilling the demand for effective control, and that VP1 subunit vaccines remain promising vaccine strategies that require further refinement...
  38. pmc Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    Iliyana Mikell
    Seattle BioMed, Seattle, Washington, USA
    PLoS Pathog 7:e1001251. 2011
    ....
  39. ncbi Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus
    Kathy Hancock
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 361:1945-52. 2009
    ....
  40. pmc Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    Nicole A Doria-Rose
    LIR, NIAID, National Institutes of Health, Bldg 10, Rm 7N246, 10 Center Dr, Bethesda, MD 20892, USA
    J Virol 83:188-99. 2009
    ..These data describe the breadth and titer of serum NAb and the frequency and phenotype of HIV-specific B cells in a cohort of patients with broad cross-neutralizing antibody responses that are potential goals for vaccines for HIV...
  41. ncbi HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    ..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
  42. pmc The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection
    Theodore C Pierson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 1:135-45. 2007
    ..Thus, neutralization is best described by a model requiring "multiple hits" with the cumulative functional outcome determined by interplay between antibody affinity and epitope accessibility...
  43. pmc Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection
    Simon D W Frost
    Department of Pathology, University of California at San Diego, La Jolla, CA 92093 0679, USA
    Proc Natl Acad Sci U S A 102:18514-9. 2005
    ..Our results suggest that autologous neutralizing antibody responses may play a pivotal role in the diversification of HIV-1 envelope during the early stages of infection...
  44. ncbi Structural basis of West Nile virus neutralization by a therapeutic antibody
    Grant E Nybakken
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nature 437:764-9. 2005
    ..Collectively, our results suggest that a vaccine strategy targeting the dominant DIII epitope may elicit safe and effective immune responses against flaviviral diseases...
  45. ncbi A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    Simon Beddows
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W 805, New York, NY 10021, USA
    Virology 360:329-40. 2007
    ..When antibodies able to neutralize HIV-1(JR-FL) were detected, antigen depletion studies showed they were not directed at the V3 region but were targeted at other, undefined gp120 and also non-gp120 epitopes...
  46. pmc Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody
    W M P B Wahala
    Department of Microbiology and Immunology, CB 7290 University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Virology 392:103-13. 2009
    ..Our results have implications for understanding protective immunity following natural DENV infection and for evaluating DENV vaccines...
  47. ncbi Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand
    Timothy P Endy
    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, United States Army Medical Research and Materiel Command, Ft Detrick, Maryland, USA
    J Infect Dis 189:990-1000. 2004
    ..Most DHF cases occur after sequential heterotypic DV infections. The role of preexisting humoral immunity in modifying severity of dengue disease is not well understood...
  48. ncbi Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design
    E O Saphire
    Department of Molecular Biology, Department of Immunology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 293:1155-9. 2001
    ..The structure, together with mutagenesis studies, provides a rationale for the extensive cross-reactivity of b12 and a valuable framework for the design of HIV-1 vaccines capable of eliciting b12-like activity...
  49. pmc Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3027, USA
    J Virol 84:8098-110. 2010
    ..The structural and functional details of extraordinary CDR H3 and extensive affinity maturation provide insights into the neutralization mechanism of and the elicitation pathway for broadly neutralizing antibodies like PG9 and PG16...
  50. pmc Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:10892-905. 2001
    ..g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design...
  51. ncbi An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
    Elisabetta Traggiai
    Institute for Research in Biomedicine, Via Vela 6, CH 6500 Belllinzona, Switzerland
    Nat Med 10:871-5. 2004
    ..These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection...
  52. ncbi Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo
    Thomas von Hahn
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10021, USA
    Gastroenterology 132:667-78. 2007
    ....
  53. pmc Role of HIV membrane in neutralization by two broadly neutralizing antibodies
    S Munir Alam
    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 106:20234-9. 2009
    ..These results bear directly on strategies for rational design of HIV-1 envelope immunogens...
  54. ncbi Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides
    Damian Guang Wei Foo
    Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
    Virus Res 125:61-8. 2007
    ..Altogether, these data indicate that SP70 represents a promising candidate for an effective synthetic peptide-based vaccine against EV71...
  55. pmc Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
    Penny L Moore
    Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA
    J Virol 80:2515-28. 2006
    ..We hypothesize that these nonfunctional forms of Env on particle surfaces serve to divert the antibody response, helping the virus to evade neutralization...
  56. pmc Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways
    Rong Rong
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    PLoS Pathog 5:e1000594. 2009
    ....
  57. ncbi Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
    Shee Mei Lok
    Department of Biological Sciences, Purdue University, 915 West State Street, West Lafayette, Indiana 47907 2054, USA
    Nat Struct Mol Biol 15:312-7. 2008
    ..The changes in the structure of the viral surface are presumably responsible for inhibiting attachment to cells...
  58. pmc Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Instiutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10724-37. 2004
    ..Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed...
  59. pmc Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein
    Mario Perotti
    Laboratorio di Microbiologia e Virologia, Universita Vita Salute San Raffaele, DIBIT2, Via Olgettina 60, 20132 Milano, Italia
    J Virol 82:1047-52. 2008
    ..Fab e137 was also able to inhibit cell culture-grown HCV (genotype 2a). These data indicate that broadly cross-reacting and cross-neutralizing antibodies are generated during HCV infection...
  60. ncbi The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
    Gunilla B Karlsson Hedestam
    Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Nat Rev Microbiol 6:143-55. 2008
    ..Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens...
  61. pmc Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein
    Ania M Owsianka
    Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK
    J Gen Virol 89:653-9. 2008
    ..This suggests that CBH-5 inhibits HCV infection by competing directly with CD81 for a binding site on E2...
  62. pmc Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins
    George Sellhorn
    Seattle BioMed, Seattle, Washington, USA
    J Virol 86:128-42. 2012
    ..The heterotrimeric gp140s elicited broader anti-tier 1 isolate neutralizing antibody responses than did the homotrimeric gp140s...
  63. pmc PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
    Emilia Falkowska
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA
    J Virol 86:4394-403. 2012
    ....
  64. pmc Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant
    Xueling Wu
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    J Virol 80:835-44. 2006
    ....
  65. pmc Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion
    Blaise Corthesy
    R and D Laboratory of the Division of Immunology and Allergy, DMI CHUV, Rue du Bugnon, 1011 Lausanne, Switzerland
    J Virol 80:10692-9. 2006
    ..These findings identify a mechanism whereby the well-conserved immunodominant VP6 protein can function as a target for heterotypic antibodies and protective immunity...
  66. pmc Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2
    Soila Sukupolvi-Petty
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Box 8051, St Louis, MO 63110, USA
    J Virol 84:9227-39. 2010
    ..Overall, these studies define the structural and functional complexity of antibodies against DENV-2 with protective potential...
  67. pmc Enhanced HIV-1 neutralization by antibody heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:875-80. 2012
    ..Heterotypic bivalent binding enhanced neutralization compared with the parental antibodies. We conclude that antibody recognition and viral neutralization of HIV can be improved by heteroligation...
  68. pmc Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice
    Tao Meng
    Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore
    PLoS ONE 6:e21757. 2011
    ..VP1 is one of the major immunogenic capsid protein of EV71 and plays a crucial role in viral infection. Antibodies against VP1 are important for virus neutralization...
  69. pmc Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins
    Taia T Wang
    Department of Microbiology Mount Sinai School of Medicine New York, New York, United States of America
    PLoS Pathog 6:e1000796. 2010
    ..Importantly, our antibodies are of naturally occurring specificity rather than selected from cloned libraries, demonstrating that broad-spectrum humoral immunity to influenza viruses can be elicited in vivo...
  70. pmc International network for comparison of HIV neutralization assays: the NeutNet report
    Eva Maria Fenyo
    Department of Microbiology, Dermatology and Infection, University of Lund, Lund, Sweden
    PLoS ONE 4:e4505. 2009
    ..To address this, an international collaboration (NeutNet) involving 18 independent participants was organized to compare different assays...
  71. pmc Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity
    Manish Sagar
    Department of Medicine, Brigham and Women s Hospital, Cambridge, Massachusetts 02139, USA
    J Virol 80:9586-98. 2006
    ..These studies suggest that changes within the V1-V2 envelope domains over the course of an infection influence sensitivity to autologous neutralizing antibodies and may also impact host receptor/coreceptor interactions...
  72. pmc Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
    Anne Piantadosi
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 83:10269-74. 2009
    ..Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection...
  73. pmc Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization
    Steevenson Nelson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 4:e1000060. 2008
    ..Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV...
  74. ncbi Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
    Diana V Pastrana
    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892 4263, USA
    Virology 321:205-16. 2004
    ..The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies...
  75. ncbi Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    Rosa M F Cardoso
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Immunity 22:163-73. 2005
    ..These structural insights should assist in the design of immunogens to elicit 4E10-like neutralizing responses...
  76. pmc Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
    Mayla Hsu
    Aaron Diamond AIDS Research Center and Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:7271-6. 2003
    ..However, HIV-HCV pseudotype infectivity was inhibited by a recombinant soluble form of CD81 and a mAb specific for CD81, suggesting that CD81 may be a component of a receptor complex...
  77. ncbi Measuring HIV neutralization in a luciferase reporter gene assay
    David C Montefiori
    Department of Surgery, Laboratory for AIDS, Vaccine Research and Development, Duke University Medical Center Durham, NC, USA
    Methods Mol Biol 485:395-405. 2009
    ..This assay has become the main endpoint neutralization assay used by the NIH-sponsored HIV Vaccine Trials Network and by a growing number of laboratories worldwide...
  78. pmc Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
    Elin S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 83:8925-37. 2009
    ....
  79. pmc B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus
    Michael S Diamond
    Department of Medicine, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
    J Virol 77:2578-86. 2003
    ..We conclude that antibodies and B cells play a critical early role in the defense against disseminated infection by WNV...
  80. pmc Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop
    Penny L Moore
    National Institute for Communicable Diseases of the NHLS, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 85:3128-41. 2011
    ....
  81. pmc Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC
    Tara G Edmonds
    Department of Molecular and Cellular Pathology, University of Alabama at Birmingham, 701 19th Street South, Birmingham, AL 35294, USA
    Virology 408:1-13. 2010
    ..In PBMC, NAb activity can be analyzed either within a single or multiple cycles of replication. These results represent advancement toward a standardizable PBMC-based neutralization assay for assessing HIV-1 vaccine immunogen efficacy...
  82. ncbi Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan
    Luan Yin Chang
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Children s Hospital, Chang Gung University, Taoyuan, Taiwan
    Pediatrics 109:e88. 2002
    ..We measured EV71 seroprevalence rates before and after the epidemic and investigated risk factors associated with EV71 infection and illness...
  83. pmc An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys
    Minetaro Arita
    Department of Virology II, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama shi, Tokyo 208 0011, Japan
    J Virol 81:9386-95. 2007
    ..In the CNS, EV71(S1-3') was isolated only from the spinal cord. These results indicate that EV71(S1-3') acts as an effective antigen, although this attenuated strain was still neurotropic when inoculated via the intravenous route...
  84. pmc Rapid evolution of the neutralizing antibody response to HIV type 1 infection
    Douglas D Richman
    Department of Pathology, Veterans Affairs San Diego Healthcare System and the University of California at San Diego, La Jolla, CA 92093 0679, USA
    Proc Natl Acad Sci U S A 100:4144-9. 2003
    ..These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection...
  85. pmc Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism
    Dai Wang
    Department of Molecular Biology, Princeton University, NJ 08544, USA
    Proc Natl Acad Sci U S A 102:18153-8. 2005
    ....
  86. ncbi Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge
    Yao Chi Chung
    Department of Chemical Engineering, National Tsing Hua University, Hsinchu 300, Taiwan
    Vaccine 26:1855-62. 2008
    ..These data collectively indicate the importance of the preservation of VLP structure and implicate the potential of VLP as a vaccine to prevent EV71 infection...
  87. ncbi Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide
    Damian Guang Wei Foo
    Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, MD4A, 5 Science Drive 2, Singapore 117597, Singapore
    Microbes Infect 9:1299-306. 2007
    ..In conclusion, EV71-neutralizing antibodies elicited by the synthetic peptide SP70 were able to confer good in vivo passive protection against homologous and heterologous EV71 strains in suckling Balb/c mice...
  88. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  89. ncbi Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
    J E Schmitz
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Science 283:857-60. 1999
    ..These results confirm the importance of cell-mediated immunity in controlling HIV-1 infection and support the exploration of vaccination approaches for preventing infection that will elicit these immune responses...
  90. ncbi Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
    Victoria R Polonis
    Walter Reed Army Institute of Research, Washington, DC, USA
    Virology 375:315-20. 2008
    ....
  91. ncbi Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
    Bernard J Cohen
    Centre for Infections, Health Protection Agency, London NW9 5EQ, UK
    Vaccine 26:59-66. 2007
    ..Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy...
  92. ncbi Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus
    M Lemaitre
    UPMC, Univ Paris 6, UMR S 707, Paris, France
    Clin Microbiol Infect 17:732-7. 2011
    ..0001). Seasonal 2007 H1N1 infection is an independent predictor of elevated pre-exposure antibody titers against 2009 pH1N1 and may have contributed to lowering the burden of the 2009 pH1N1 pandemic...
  93. pmc Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission
    Li Wu
    HIV Drug Resistance Program, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Virol 76:5905-14. 2002
    ..While these findings do not discount the role of intercellular contact in facilitating HIV-1 transmission, our in vitro data indicate that DC-SIGN interactions with ICAM-3 do not promote DC-SIGN-mediated virus transmission...
  94. ncbi HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  95. pmc Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
    Amandeep K Dhillon
    The Scripps Research Institute, Department of Immunology IMM 2, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 81:6548-62. 2007
    ..The most likely epitope recognized by the monomeric gp120 binding neutralizing fraction is the CD4 binding site, although other epitopes, such as the glycan shield, cannot be excluded...
  96. pmc Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II
    Chih Yun Lai
    Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Virol 82:6631-43. 2008
    ..These findings have implications for our understanding of the pathogenesis of dengue and for the future design of subunit vaccine against DENV as well...
  97. pmc H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol 85:10945-54. 2011
    ..These findings represent the first report describing the quality of the antibody responses in humans following AIV VLP immunization and support further development of such vaccines against emerging influenza virus strains...
  98. pmc Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors
    Mieke C Sprangers
    Vaccine R and D Division, Crucell Holland BV, 2301 CA Leiden, The Netherlands
    J Clin Microbiol 41:5046-52. 2003
    ..Based on simplicity, speed, high throughput, sensitivity, and robustness, we propose a qualified assay in which Ad neutralization is monitored by luciferase reporter gene expression...
  99. pmc Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    Aran F Labrijn
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:10557-65. 2003
    ..The results identify hurdles in using CD4i epitopes as targets for antibody-mediated neutralization in vaccine design but also indicate that the CD4i regions could be efficiently targeted by small molecule entry inhibitors...
  100. pmc Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines
    R J Wool-Lewis
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia 19104 6076, USA
    J Virol 72:3155-60. 1998
    ....
  101. ncbi Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression
    Marit J van Gils
    Department of Experimental Immunology, Landsteiner Laboratory Sanquin Research, and Center for Infection and Immunity CINIMA, Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands
    AIDS 23:2405-14. 2009
    ..However, little is known about the prevalence of naturally occurring broadly neutralizing activity in serum of HIV-1-infected individuals...

Research Grants68

  1. Ecological impacts of forest disturbance on La Crosse encephalitis virus dynamics
    MARIA RICHETTA CAMILLE HARRIS; Fiscal Year: 2010
    ..Plaque reduction neutralization tests will be employed to assess LAC antibody prevalence in mammals...
  2. ESCHERICHIA COLI LT-RELATED ENTEROTOXINS
    RICHARD FINKELSTEIN; Fiscal Year: 1991
    ..immunosorption assays (ELISA), latex particle agglutination tests (LPAT), immuno-blotting precipitin and neutralization tests) using polyclonal and monoclonal antibodies; b) production, isolation, purification and characterization of ..
  3. ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES
    Linda Saif; Fiscal Year: 2006
    ..will be quantitated in intestinal, tonsillar, and systemic lymphoid tissues using ELISPOT, LPA, FACS, neutralization tests, and ELISA...
  4. RECOMBINANT DENGUE VIRUS ANTIGEN PRODUCTION
    Helene Paxton; Fiscal Year: 2000
    ..sera and mouse antibodies representing a range of specificities and titers determined by IFA, ELISA, and neutralization tests. Stability tests will be initiated...
  5. CULTIVATION OF VIRUSES IN INFLAMMATORY BOWEL DISEASE
    Gary Gitnick; Fiscal Year: 1980
    ..against tissue culture grown viruses with appropriate control materials will be prepared and specific neutralization tests will be undertaken...
  6. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  7. DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE
    Barton Haynes; Fiscal Year: 2003
    ..abstract_text> ..
  8. Genotypic and Phenotypic Analysis of West Nile virus, Yucatan Peninsula of Mexico
    Bradley Blitvich; Fiscal Year: 2008
    ..This information will help determine why there has not been an epidemic of WNV in the YP, and will identify risk factors associated with WNV disease. [unreadable] [unreadable] [unreadable]..
  9. LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS
    Thomas Monath; Fiscal Year: 2002
    ..abstract_text> ..
  10. Novel Biological Activities of Anti-Viral Antibody
    Donald Forthal; Fiscal Year: 2006
    ..This project may provide crucial insights for guiding the development of vaccines, immunoprophylaxis and immunotherapy. ..
  11. Pathogenesis of RSV disease in the Elderly
    Edward Walsh; Fiscal Year: 2008
    ..abstract_text> ..
  12. Human Metapneumovirus Infections in Children
    John Williams; Fiscal Year: 2004
    ..The specific aims of this study are to define the prevalence of hMPV infection in children, describe fully the spectrum of clinical illness and identify serologic markers of seroconversion and correlates of immunity. ..
  13. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2007
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  14. Human monoclonal panel mimicking anthrax immune globulin
    Donald Reason; Fiscal Year: 2005
    ..The PA-specific panel we construct will be molecularly defined and characterized, incorporate the advantages of toxin-specific, polyclonal human sera, and lack the inherent risk associated with blood derived products. ..
  15. MOLECULAR DETERMINANTS OF HUMAN PNEUMOCOCCAL IMMUNITY
    Donald Reason; Fiscal Year: 2004
    ..Understanding the molecular mechanisms that shape the human antibody repertoire to pneumococcal polysaccharides may also suggest strategies that would facilitate the development of more efficacious vaccines. ..
  16. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  17. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2008
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  18. Structural determinants of human immunity to anthrax
    Donald Reason; Fiscal Year: 2008
    ..anthracis infection. In addition, the antibodies isolated will constitute a panel of fully human monoclonal binding domains with potential for therapeutic use as passive immunogens. [unreadable] [unreadable] [unreadable]..
  19. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  20. HIV Vaccine Development
    David Montefiori; Fiscal Year: 2003
    ....
  21. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  22. Mucosal Protection Against HIV Transmission by Combinations of Anti-HIV Antibodie
    Lisa Cavacini; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  23. Determinanats of Protective Immunity to Metapneumovirus
    John Williams; Fiscal Year: 2005
    ..The proposed work will provide the candidate skills and experience to be an outstanding physician-scientist in the field of human viral immunology. ..
  24. ANTIBODIES AGAINST HIV-1 gp41: TOOLS FOR VACCINE DESIGN
    Michael Zwick; Fiscal Year: 2005
    ..A panel of mAbs against the described epitopes on gp41 will provide valuable tools to aid in HIV-1 vaccine design. ..
  25. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2005
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  26. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  27. HERPES SIMPLEX VIRUS FC RECEPTOR
    Harvey Friedman; Fiscal Year: 2009
    ..This proposal addresses fundamental properties of HSV-1 gE, gl and Us9 related to infection of neurons and immune evasion. Understanding these activites may lead to novel therapies and better vaccines. ..
  28. SARS Reverse Genetics
    Ralph Baric; Fiscal Year: 2008
    ..The goal of this application is to establish genetic control over the SARS genome and provide uniform reagents that will be used by other groups throughout the country. ..
  29. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2004
    ....
  30. Human Metapneumovirus Infection in Adults
    ANN FALSEY; Fiscal Year: 2007
    ..abstract_text> ..
  31. Mechanism of Antibody Neutralization of Viruses
    Xinzhen Yang; Fiscal Year: 2010
    ..to define such exact requirements that will be used as guiding posts for developing effective vaccine against HIV-1 infection, which is the ultimate weapon in combating the HIV-1/AIDS pandemic within this country and around the globe ..
  32. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
    Shibo Jiang; Fiscal Year: 2010
    ..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
  33. Towards a Vaccine for the Common Cold
    THOMAS JAMES SMITH; Fiscal Year: 2010
    ..If successful, the methods developed here will also yield a rapid way to identify potential, conserved, vaccine targets for other antigenically diverse viruses as well. ..
  34. IMMUNE PROMOTION OF REMYELINATION
    Moses Rodriguez; Fiscal Year: 2008
    ..Our findings are expected to provide new insights into the enhancement of remyelination in diseases such as multiple sclerosis. [unreadable] [unreadable]..
  35. The vital role of BAFF in the development of SLE
    William Stohl; Fiscal Year: 2010
    ..abstract_text> ..
  36. Natural history of acute and chronic HCV in blood donors
    Michael Busch; Fiscal Year: 2008
    ..These investigations will yield important insights into HCV pathogenesis and clarify the natural history of disease for the large number of HCV infected persons identified through donor screening. ..
  37. Broad Neutralization of HIV-1 from Rhinoviruses Displaying gp41 MPER Sequences
    GAIL ARNOLD; Fiscal Year: 2009
    ....
  38. Mechanism of SHeA2 Action in Ovarian Cancer
    Doris Benbrook; Fiscal Year: 2009
    ..The elucidation of the proteins involved in the SHetA2 pathwayswill provide potential biomarkers for ovarian cancer diagnosis, prevention and treatment strategies. ..
  39. Cell Surface Modulation of EGFR-Mediated Differentiation
    Suil Kim; Fiscal Year: 2008
    ....
  40. Natural History and Pathogenesis of WNV in Viremic Dono*
    Michael Busch; Fiscal Year: 2007
    ..abstract_text> ..
  41. ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
    Paul Goepfert; Fiscal Year: 2006
    ..Recently, the Alabama clinic enrolled 125 higher-risk gay men in <5 months in the first US phase III trial. Plans for utilizing these cohorts and others are described. ..
  42. The regulation of tumor immunity by NKT cells
    Mark Smyth; Fiscal Year: 2007
    ..This proposal focuses clearly on a pivotal immune control mechanism that will influence many current and future immunotherapies. ..
  43. MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY
    JULIA HURWITZ; Fiscal Year: 2001
    ..Jude Children's Research Hospital (SJCRH), predicting successful implementation of the proposed studies. ..
  44. 9th Annual International Mtg on HIV Dynamics & Evolution
    Douglas Richman; Fiscal Year: 2002
    ..Participants in the 9th Meeting will include leading figures in virology, biomathematics, and evolution, as well as junior workers actively involved in research in these areas. ..
  45. ENHANCEMENT OF HIV IMMUNOGENICITY BY INFLUENZA VIRUS
    Qizhi Yao; Fiscal Year: 2002
    ..We will be especially interested in testing in CD4+ T cell knock-out mice if such immunization can also induce antibody responses to HIV and whether HIV specific neutralizing antibody responses will also be induced. ..
  46. INTERFERON IN MODULATING DENGUE VIRUS INFECTION
    Michael Diamond; Fiscal Year: 2002
    ....
  47. Hamster Model for AIDS Lymphomas
    JANET BUTEL; Fiscal Year: 2003
    ..In addition, this project may provide new insights into lymphomagenesis in general and may lead to the development of new diagnostic and therapeutic approaches to this malignancy. ..
  48. Functional Analysis of HCV-B Lymphocyte Interactions
    Thomas Chambers; Fiscal Year: 2003
    ..abstract_text> ..
  49. Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Raphael Dolin, Dean for Clinical Programs, Harvard Medical School, will guide Dr. Barouch's development as an independent investigator. In addition, a committee of distinguished scientists will oversee his progress toward independence. ..
  50. Development of Novel Antiviral Agents VS West Nile Virus
    Michael Diamond; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  51. Orexinergic Pathways in Central Autonomic Control
    WILLIS SAMSON; Fiscal Year: 2005
    ..abstract_text> ..
  52. Dock and Lock: novel protein engineering
    Chien Hsing Chang; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  53. A VEE Replicon-Based Vaccine for Dengue Virus
    Laura White; Fiscal Year: 2006
    ..abstract_text> ..
  54. HIV Vaccine Trials in Women
    Beryl Koblin; Fiscal Year: 2006
    ..The primary outcomes to be compared are measures of unprotected sex and vaccine knowledge scores. ..
  55. SELECTING ENV TRIMERS IN HIV-VLP VACCINE PRESENTATIONS
    James Binley; Fiscal Year: 2007
    ..In Specific Aim 3, we will test the immunogenicity of i) pseudovirions bearing only functional trimers and ii) receptor-engaged pseudovirions attached to autologous macaque lymphocytes. ..
  56. Immune Responses to Biodefense Vaccines Early in Life
    Marcela F Pasetti; Fiscal Year: 2010
    ..It will also provide knowledge to better understand the mechanisms mediating neonatal-infant immunity to develop more effectivevaccines to prevent diseases early in life. ..
  57. Determinants of RNA virus evolution
    ISABEL NOVELLA; Fiscal Year: 2009
    ....
  58. REVERSE GENETICS WITH A CORONAVIRUS INFECTIOUS CONSTRUCT
    Ralph Baric; Fiscal Year: 2004
    ..The assembly of a full-length TGE construct is an important breakthrough for coronavirus research and will benefit all aspects of coronavirus pathogenesis, molecular biology, epidemiology and biochemistry. ..
  59. Remodeling SARS Coronavirus Genome Regulatory Networks
    Ralph Baric; Fiscal Year: 2004
    ..abstract_text> ..
  60. A longitudinal study of HIV-1 infection in Uganda
    MARCEL CURLIN; Fiscal Year: 2006
    ..These hypotheses will be tested by longitudinal sampling and phylogenetic analysis of viral genes in rapidly progressing and slowly progressing Ugandans infected with HIV-1 subtypes A and D. ..
  61. Standardizing Measurements of HIV-specific CD8+ T Cells
    Xia Jin; Fiscal Year: 2004
    ..Finally, we will revalidate the ICS assay in PBMC obtained from the HIV Vaccine Trials Network to assess levels of CD8+ T cell responses among recipients of HIV vaccines. ..
  62. DNA VACCINE IMMUNITY TO HIV1 AND SIV
    Norman Letvin; Fiscal Year: 2002
    ..This aim therefore studies cross reactivity to a single epitope not multi epitopes. ..
  63. Microbial siderophore-specific innate immune responses
    Roland Strong; Fiscal Year: 2008
    ....